S2-Leitlinie zur Diagnostik und Therapie der sekundären Eisenüberladung bei Patienten mit angeborenen Anämien
Standard
S2-Leitlinie zur Diagnostik und Therapie der sekundären Eisenüberladung bei Patienten mit angeborenen Anämien. / Cario, H; Grosse, R; Janssen, G; Jarisch, A; Meerpohl, J; Strauss, G; German hematology societies (GPOH and DGHO).
in: KLIN PADIATR, Jahrgang 222, Nr. 6, 6, 11.2010, S. 399-406.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - S2-Leitlinie zur Diagnostik und Therapie der sekundären Eisenüberladung bei Patienten mit angeborenen Anämien
AU - Cario, H
AU - Grosse, R
AU - Janssen, G
AU - Jarisch, A
AU - Meerpohl, J
AU - Strauss, G
AU - German hematology societies (GPOH and DGHO)
N1 - © Georg Thieme Verlag KG Stuttgart · New York.
PY - 2010/11
Y1 - 2010/11
N2 - In Germany and Central Europe, congenital disorders leading to secondary hemochromatosis are rare. The majority of these patients are treated in peripheral medical institutions. As a consequence, the experience of each institution in the treatment of secondary hemochromatosis in patients with congenital anemia is limited. Recent developments concerning new chelating agents, their combination for intensified chelation and new possibilities to diagnose and monitor iron overload have important consequences for the management of patients with secondary hemochromatosis and increase its complexity enormously. Therefore, the development of a guideline for rational and efficient diagnostics and treatment was necessary. The new guideline was developed within a formal consensus process and finally approved by a consensus conference with participants from both the pediatric and adult German hematology societies (GPOH and DGHO). Apart from general information and recommendations, the guideline contains 9 consensus statements on diagnostics (iron status, siderotic complications, chelator side-effects), the start of chelation, indications for intensified chelation, iron elimination in specific disorders, and iron elimination after stem cell transplantation. Here, these consensus statements are presented and discussed in detail. For the complete text of the guideline, please visit the AWMF homepage at http://www.leitlinien.net .
AB - In Germany and Central Europe, congenital disorders leading to secondary hemochromatosis are rare. The majority of these patients are treated in peripheral medical institutions. As a consequence, the experience of each institution in the treatment of secondary hemochromatosis in patients with congenital anemia is limited. Recent developments concerning new chelating agents, their combination for intensified chelation and new possibilities to diagnose and monitor iron overload have important consequences for the management of patients with secondary hemochromatosis and increase its complexity enormously. Therefore, the development of a guideline for rational and efficient diagnostics and treatment was necessary. The new guideline was developed within a formal consensus process and finally approved by a consensus conference with participants from both the pediatric and adult German hematology societies (GPOH and DGHO). Apart from general information and recommendations, the guideline contains 9 consensus statements on diagnostics (iron status, siderotic complications, chelator side-effects), the start of chelation, indications for intensified chelation, iron elimination in specific disorders, and iron elimination after stem cell transplantation. Here, these consensus statements are presented and discussed in detail. For the complete text of the guideline, please visit the AWMF homepage at http://www.leitlinien.net .
KW - Anemia, Aplastic
KW - Anemia, Diamond-Blackfan
KW - Anemia, Dyserythropoietic, Congenital
KW - Anemia, Sickle Cell
KW - Chelating Agents
KW - Child
KW - Deferoxamine
KW - Erythrocyte Transfusion
KW - Ferritins
KW - Germany
KW - Hematopoietic Stem Cell Transplantation
KW - Hemochromatosis
KW - Hemosiderosis
KW - Humans
KW - beta-Thalassemia
U2 - 10.1055/s-0030-1265178
DO - 10.1055/s-0030-1265178
M3 - SCORING: Zeitschriftenaufsatz
C2 - 20862634
VL - 222
SP - 399
EP - 406
JO - KLIN PADIATR
JF - KLIN PADIATR
SN - 0300-8630
IS - 6
M1 - 6
ER -